Ruta D. Rao, MD

Articles by Ruta D. Rao, MD

Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC

May 8th 2023

Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC

ByRuta D. Rao, MD

April 17th 2023

Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Ruta D. Rao, MD

Articles by Ruta D. Rao, MD

Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC

Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma